Stock Market & Financial News
Morgan Stanley (MS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Morgan Stanley (MS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MS Analysts Estimate Conagra Brands (CAG) to Report a Decline in Earnings: What to Look Out for
Conagra Brands (CAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAG BNY (BNY) Reports Next Week: Wall Street Expects Earnings Growth
BNY (BNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BNY M&T Bank Corporation (MTB) Reports Next Week: Wall Street Expects Earnings Growth
M&T Bank (MTB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MTB 
First Horizon National (FHN) Reports Next Week: Wall Street Expects Earnings Growth
First Horizon (FHN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FHN 
Analysts Estimate Elevance Health (ELV) to Report a Decline in Earnings: What to Look Out for
Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ELV 
The PNC Financial Services Group, Inc (PNC) Reports Next Week: Wall Street Expects Earnings Growth
The PNC Financial Services Group (PNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PNC 
Progressive (PGR) Expected to Beat Earnings Estimates: Should You Buy?
Progressive (PGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PGR 
Cintas (CTAS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Cintas (CTAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CTAS 
Community Trust Bancorp (CTBI) to Report Q2 Results: Wall Street Expects Earnings Growth
Community Trust Bancorp (CTBI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CTBI 
Earnings Preview: Great Southern Bancorp (GSBC) Q2 Earnings Expected to Decline
Great Southern Bancorp (GSBC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSBC 
United Airlines (UAL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
United (UAL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UAL 
JB Hunt (JBHT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
JB Hunt (JBHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JBHT 
Three Most Valuable Companies at $13 Trillion: Buy, Sell, or Hold
The three most valuable companies in the world, NVIDIA (NASDAQ:NVDA | NVDA Price Prediction), Apple (NASDAQ:AAPL), and Google parent Alphabet (NASDAQ:GOOG), collectively command a combined market cap north of $13 trillion and sit at the center of the AI capex boom.
AAPL 
EUR/USD outlook undermined further by US-Iran escalation
The EUR/USD edged only slightly lower, showing surprising resilience for now while European equity markets took the brunt of the sell-off, as tensions in the Middle East made an unwelcome return with renewed intensity. A sharp rebound in crude oil prices has quickly become the dominant market theme again, overshadowing economic data and forcing investors back into defensive positions.
Digital Turbine Stock Soars 108% YTD: Is There More Room for Growth?
APPS stock's 108% YTD rally is backed by AI-driven monetization, global expansion, improving estimates and discounted valuation.
APPS 
Block's Square Growth Engine: Can GPV Keep Accelerating?
XYZ's Square accelerates GPV growth through global expansion, larger sellers and new commerce tools, strengthening payment activity across its ecosystem.
SQ 
BOTJ vs. CFFI: Which Regional Bank Stock Looks More Attractive Now?
Bank of the James's earnings surge, efficiency gains, healthier asset quality and lower valuation make it look more attractive than C&F Financial for capital appreciation.
BOTJ 
Can CRS Achieve Its Upbeat FY26 Operating Income Guidance?
Carpenter Technology lifts its FY26 operating income outlook after a record third quarter, driven by aerospace and defense demand, pricing, and volume gains.
CRS 
AU's Free Cash Flow Soars 190% in Q1: Is More Growth Ahead?
AngloGold Ashanti posts $1.2B free cash flow in Q1'26 as higher gold prices, steady production and cost discipline fuel results.
AU 
3 Blue-Chip Retail Stocks to Trust as Volatility Favors Quality
TJX, COST and WMT combine scale, dividends and resilient retail models as market volatility pushes investors toward quality blue-chip retail stocks.
COST 
Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know
The mean of analysts' price targets for Bioventus (BVS) points to a 28.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BVS 
Bassett Furniture (BSET)'s Technical Outlook is Bright After Key Golden Cross
Bassett Furniture Industries, Incorporated (BSET) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BSET's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
BSET 
Wall Street Analysts Predict a 25.33% Upside in Entegris (ENTG): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Entegris (ENTG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ENTG 
LATAM (LTM) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, LATAM Airlines Group S.A. (LTM) is looking like an interesting pick, as it just reached a key level of support.
LTM 
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
The consensus price target hints at a 61.5% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NVCT 
Does GXO Logistics (GXO) Have the Potential to Rally 36.13% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 36.1% in GXO Logistics (GXO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GXO 
Shell forecasts upgraded as brokers account for the incremental positives
Shell Plc's (LSE:SHEL, NYSE:SHEL) second-quarter update has pushed brokers to raise forecasts, with Citi lifting its EPS estimate by 13% and Jefferies increasing its earnings forecast by 14% to around US$9 billion. Citi said the statement was “incrementally positive”, with the main upside coming from downstream.
SHEL 
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript
MCRB 
Want Anthropic Exposure Before the IPO? These 2 AI Giants Are Already There
Nearly a month after SpaceX NASDAQ: SPCX held its highly anticipated and record-breaking IPO, investors hoping for a continuation of the AI-driven market rally are looking forward to the next big public debut of 2026: Anthropic, the maker of the Claude family of AI models.
AMZN 
